Dendreon Corp fka DNDNQ

[DewDiligence]

>If I understand what poster DewDiligence is saying, selection bias (program-survival bias) is observed because companies can cherry-pick results to present from Phase 2 trials but it cannot do the same with subsequent Phase 3 trials?<

The issue I’m talking about is not cherry picking but rather attrition. The efficacy observed in phase-2 programs that end up advancing to phase-3 is biased on the high side relative to the true efficacy of the drugs in question. This bias is either underestimated or not understood by many biotech investors. Regards, Dew